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In the [research design and methods]{.smallcaps} section in the print version of the article listed above, GLP-1 and GIP infusion concentrations have reverse order as compared to the original publication (ref. 22). The correct order is as follows: "At *t* = −2 min, a bolus of either GLP-1 or GIP was infused to increase the plasma concentration to approximately 120 and 1,000 pmol/L, respectively. At *t* = 0 min, a continuous infusion of GLP-1 or GIP (60 or 240 pmol/kg ⋅ h, respectively) was initiated and terminated at *t* = 120 min." The online version reflects these changes.
